Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 1.558 EUR -0.76% Market Closed
Market Cap: 99.4m EUR
Have any thoughts about
Oryzon Genomics SA?
Write Note

EV/EBIT
Enterprise Value to EBIT

-21.4
Current
-23.7
Median
4.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-21.4
=
Enterprise Value
95.9m EUR
/
EBIT
-4.5m EUR
All Countries
Close
Market Cap EV/EBIT
ES
Oryzon Genomics SA
MAD:ORY
98.1m EUR -21.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 25.3
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 9.9
US
Epizyme Inc
F:EPE
94.1B EUR -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 17.7
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
34.8B EUR -76.9
EBIT Growth
ES
Oryzon Genomics SA
MAD:ORY
Average EV/EBIT: 22.5
Negative Multiple: -21.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.9 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-14.3
2-Years Forward
EV/EBIT
-21.2
3-Years Forward
EV/EBIT
-20

See Also

Discover More